Metabolic Tumor Heterogeneity Hints at NSCLC PrognosisMetabolic Tumor Heterogeneity Hints at NSCLC Prognosis

Can glucose metabolic heterogeneity signal prognosis in non-small cell lung cancer (NSCLC) patients treated with erlotinib? Medscape Radiology
Source: Medscape Radiology Headlines - Category: Radiology Tags: Radiology Viewpoint Source Type: news

Related Links:

miR‑671‑3p is downregulated in non‑small cell lung cancer and inhibits cancer progression by directly targeting CCND2. Mol Med Rep. 2019 Jan 15;: Authors: Yao Y, Zhou Y, Fu X Abstract MicroRNAs (miRNAs) are implicated in the development and progression of non‑small cell lung cancer (NSCLC). A previous study suggested that miR‑671‑3p suppresses the development of breast cancer. However, the role of miR‑671‑3p in NSCLC remains largely unknown. In the present study, it was identified that miR‑671‑3p was significantly upregulated in NSCLC tissues compared with adjacent normal tissues by...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Conclusions: Our results firstly indentified that high levels of MEOX1 especially nuclear staining was an independent prognostic factor for NSCLC, and it served a essential roles in the regulation of cell proliferation and colony formation in vitro. It may represent a potential target for the NSCLC treatment. PMID: 30662330 [PubMed - in process]
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
ConclusionsEven if SFITGv6 demonstrates excellent affinity and specificity for αvβ6 integrin-expressing NSCLC cell lines and several NSCLC xenografts [18F]FDG-PET/CT provides an advantage over [68Ga]SFITGv6-PET/CT for the diagnosis of NSCLC patients.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
ConclusionHealthy donor-derived DNTs can target NSCLC in vitro and in vivo. DNTs recognize tumors via innate receptors which can be up-regulated by IL-15. DNTs have the potential to be used as a novel adoptive cell therapy for lung cancer either alone or in combination with IL-15.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Lung cancer experts say the recent decision to restrict the use of durvalumab immunotherapy to patients with high PD-L1 expression is'a lost therapeutic opportunity. 'Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Condition:   Non Small Cell Lung Cancer Intervention:   Drug: Apatinib(250mg/d) combined with EGFR-TKI Sponsor:   Beijing Chest Hospital Recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation Interventions:   Drug: Afatinib;   Drug: Paclitaxel Sponsor:   AZ-VUB Recruiting
Source: - Category: Research Source Type: clinical trials
Analyst, 2019, Advance Article DOI: 10.1039/C8AN02446D, PaperShichao Zhang, Zhiyao Chen, Chenrong Huang, Cheng Ding, Chang Li, Jun Chen, Jun Zhao, Liyan Miao Our method will provide a labor-saving and cost-saving tool for detecting and quantifying plasma mutations. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
In lung cancer, several potential mechanisms of intrinsic and acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been explored, including mesenchymal-epithelial transition factor (MET) signaling pathway activation. On the other hand, vascular endothelial growth factor (VEGF) production of EGFR-mutated lung cancer cells is stimulated by predominantly activated MET signaling pathway. Therefore, the inhibition of VEGF axis as the downstream target of MET signaling pathway seems promising. Here, for the first time, we report the potential efficacy of combination therapy with b...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Radiology | Tarceva